CLAIM CARD
The evidence base addressing metformin dosing and pharmacokinetic outcomes is limited in the curated corpus, with only two references providing relevant data. Shen 2025 presents a systematic review and dose-response meta-analysis focused on colorectal neoplasms prevention in adenoma-free populations, which is an indirect source for core pharmacokinetic parameters. This study provides direct pharmacokinetic data on a specific formulation, though its population consists of healthy subjects rather than patients with type 2 diabetes or other typical metformin indications.
Evidence grade: exploratory
Contradiction status: none
Publication: 5f566366-fb20-4402-ba24-c1117573f97f
Provenance: Derivation Web chain
Citation Support
source_1Zaveri 2026source_2Wu 2026source_3Hong 2026source_4Lee 2026source_5Seo 2026